We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WGBS
126
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.53M 0.08%
373,450
+134,356
+56% +$501K
FLXN
127
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.51M 0.08%
100,800
+54,445
+117% +$684K
REGN icon
128
CALL
Regeneron Pharmaceuticals
REGN
$73.1B
$1.5M 0.08%
43
-60
-58% -$23.1K
KDNY
129
CALL
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.5M 0.08%
264
-16
-6% -$972
ADMS
130
DELISTED
Adamas Pharmaceuticals
ADMS
$1.48M 0.08%
97,600
-102,290
-51% -$1.69M
SRNE
131
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.42M 0.07%
253,805
-125,995
-33% -$805K
LXRX icon
132
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
$1.41M 0.07%
+979
New +$13.3K
EXEL icon
133
CALL
Exelixis
EXEL
$14.1B
$1.39M 0.07%
1,783
OPK icon
134
CALL
Opko Health
OPK
$1.08B
$1.39M 0.07%
+1,491
New +$15.1K
PBYI icon
135
CALL
Puma Biotechnology
PBYI
$403M
$1.36M 0.07%
+458
New +$14.3K
ENLV icon
136
Enlivex Ltd
ENLV
$36.4M
$1.33M 0.07%
1,384
-506
-27% -$627K
INSM icon
137
CALL
Insmed
INSM
$22.6B
$1.33M 0.07%
1,346
+1,050
+355% +$12.3K
RIBT
138
DELISTED
RiceBran Technologies
RIBT
$1.3M 0.07%
78,548
-23,198
-23% -$344K
SCYX icon
139
SCYNEXIS
SCYX
$37.2M
$1.24M 0.06%
+7,162
New +$2.03M
EXPR
140
DELISTED
Express, Inc.
EXPR
$1.24M 0.06%
+819
New +$275K
PTCT icon
141
CALL
PTC Therapeutics
PTCT
$6.22B
$1.22M 0.06%
1,740
+740
+74% +$5.43K
FOLD
142
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.22M 0.06%
2,234
-1,251
-36% -$8.75K
RXDX
143
DELISTED
Ignyta, Inc.
RXDX
$1.22M 0.06%
225,000
+100,000
+80% +$665K
DERM
144
CALL
DELISTED
Dermira, Inc.
DERM
$1.21M 0.06%
+412
New +$11.4K
TEAR
145
DELISTED
TearLab Corporation
TEAR
$1.21M 0.06%
+188,235
New +$1.38M
COLL icon
146
Collegium Pharmaceutical
COLL
$1.18B
$1.2M 0.06%
101,410
+19,310
+24% +$319K
AERI
147
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$1.19M 0.06%
+674
New +$10.9K
CSBR icon
148
Champions Oncology
CSBR
$75.9M
$1.18M 0.06%
546,728
+251,400
+85% +$786K
SRRA
149
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.17M 0.06%
+14,750
New +$2.81M
TNXP icon
150
Tonix Pharmaceuticals
TNXP
$154M
0

Similar funds

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.